Skip to Content
Upcoming Events
There are no upcoming events available at this time.
Past Events
May 17, 2022 at 2:30 PM CEST

Tuesday May 17, 2:30-3:30 p.m. CET
West-East Roundtable: The Clinical Pathway to Europe-China Collaborations


Session Chair & Panelists:

  • Joshua Berlin, Head of Business Development, BioCentury Inc. (Session Chair)
  • Georg Büchner, Ph.D., Group Chief Business Officer, Helsinn Group
  • James Huang, Founding Managing Partner, Panacea Healthcare Venture; Managing Partner, KPCB China 
  • Stefania Mazzoleni Ph.D., Scientific Project Manager & Communication Officer, Genenta Science S.p.A
  • Steven Powell, Ph.D., CEO, eTheRNA immunotherapies N.V.
  • Debra Yu, M.D., President & Chief Strategy Officer, LianBio
  • Guo-Liang Yu, Ph.D., Chairman, BayHelix; Co-Founder, Chairman & CEO, Apollomics Inc.
May 16 - May 19, 2022
Title: Autologous Cell & Gene Therapy for the Therapeutic Targeting of Immune Payloads to the Solid Tumor Microenvironment. Preliminary results of the TEM-GBM study Type: Oral presentation during the Clinical Trials Spotlight Symposium Time: May 19, 2022, 8:45 AM – 9:00 AM ET
Washington and virtual
May 11, 2022 at 9:25 AM UTC to May 11, 2022 at 10:10 AM UTC

In person event  Venues 133 Houndsditch in London.
Go West! – Considerations For US IPOs And Dual Listings 


Moderator: Isabella Schidrich, Senior Managing Director, Nasdaq
Pierluigi Paracchi
, CEO & Co-founder, Genenta Science
Steve Hurly
, CEO, Lava Therapeutics
Piers Morgan
, CFO, Cellcentric
Fredrik Johansson
, CFO, Calliditas Therapeutics

May 5, 2022 at 5:30 PM CEST

LCA – in collaboration with Goodwin – will host the webinar “The NASDAQ IPO Path for Italian Life Science Companies: Genenta Science’s Case Study”, Speaker: Ettore Santucci (Goodwin), Pierluigi Paracchi (Genenta), Aparna Beeram (Roth Capital Partners), Federica Draghi (Genextra) and Leonardo Vingiani (Federchimica), together with Andrea Messuti (LCA)

May 5, 2022 at 11:10 AM EDT

Co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp.


Stewart Geary, CMO, Eisai
Francesco Hofmann, Head, R&D, Pierre Fabre
Cristin Hubbard, Head, Global Partnering, Diagnostics, Roche
Ryan Richardson, Chief Strategy Officer, BioNTech
Carlo Russo, CMO, Genenta Science
Moderator: Stuart Mackey, Global Head, BD, Daiichi Sankyo

Apr 28, 2022 at 8:00 AM EDT

Hosted by Genenta Science
Moderated by Brad Loncar


In this fireside chat, Genenta is delighted to bring together renowned neuro-oncologist David Reardon, MD (Harvard Medical School, Dana-Farber Cancer Institute) and Professor Luigi Naldini, MD, PhD (San Raffaele Telethon Institute for Gene Therapy), considered by many as the “father” of lentiviral gene therapy to discuss the potential application of immuno gene & cell therapy as a potential treatment for glioblastoma and other solid tumors. Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients.


Brad Loncar (CEO of Loncar Investments) will serve as the fireside chat moderator and Carlo Russo, MD (Genenta CMO & Head of Development) will also participate in the discussion.


A live question and answer session will follow.